{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:54:20Z","timestamp":1785304460943,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mesothelin is a 40-kDa glycoprotein that is highly overexpressed in various types of cancers, however molecular mechanism of mesothelin has not been well-known. Amatuximab is a chimeric monoclonal IgG1\/k antibody targeting mesothelin. We recently demonstrated that the combine therapy of Amatuximab and gemcitabine was effective for peritonitis of pancreatic cancer in mouse model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We discover the role and potential mechanism of mesothelin blockage by Amatuximab in human pancreatic cells both expressing high or low level of mesothelin in vitro experiment and peritonitis mouse model of pancreatic cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mesothelin blockage by Amatuximab lead to suppression of invasiveness and migration capacity in AsPC-1 and Capan-2 (high mesothelin expression) and reduce levels of pMET expression. The combination of Amatuximab and gemcitabine suppressed proliferation of AsPC-1 and Capan-2 more strongly than gemcitabine alone. These phenomena were not observed in Panc-1 and MIA Paca-2 (Mesothelin low expression). We previously demonstrated that Amatuximab reduced the peritoneal mass in mouse AsPC-1 peritonitis model and induced sherbet-like cancer cell aggregates, which were vanished by gemcitabine. In this study, we showed that the cancer stem cell related molecule such as ALDH1, CD44, c-MET, as well as proliferation related molecules, were suppressed in sherbet-like aggregates, but once sherbet-like aggregates attached to peritoneum, they expressed these molecules strongly without the morphological changes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our work suggested that Amatuximab inhibits the adhesion of cancer cells to peritoneum and suppresses the stemness and viability of those, that lead to enhance the sensitivity for gemcitabine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-020-07722-3","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T13:03:39Z","timestamp":1614344619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells"],"prefix":"10.1186","volume":"21","author":[{"given":"Fumihiko","family":"Matsuzawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kamachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuzo","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Einama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Kawamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moto","family":"Fukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Taketomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"7722_CR1","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"7722_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","volume":"15","author":"MA Tempero","year":"2017","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(8):1028\u201361.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"7722_CR3","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1245\/s10434-009-0409-5","volume":"16","author":"JN Vauthey","year":"2009","unstructured":"Vauthey JN, Dixon E. AHPBA\/SSO\/SSAT consensus conference on Resectable and borderline Resectable pancreatic Cancer: rationale and overview of the conference. Ann Surg Oncol. 2009;16(7):1725\u20136.","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"7722_CR4","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1002\/cncr.24410","volume":"115","author":"JA Hattangadi","year":"2009","unstructured":"Hattangadi JA, Hong TS, Yeap BY, Mamon HJ. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer. 2009;115(16):3640\u201350.","journal-title":"Cancer"},{"issue":"10","key":"7722_CR5","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","volume":"304","author":"JP Neoptolemos","year":"2010","unstructured":"Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073\u201381.","journal-title":"JAMA"},{"issue":"10041","key":"7722_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet (London, England). 2016;388(10041):248\u201357.","journal-title":"Lancet (London, England)"},{"issue":"2 Suppl 1","key":"7722_CR7","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1053\/j.seminoncol.2007.01.006","volume":"34","author":"M Ducreux","year":"2007","unstructured":"Ducreux M, Boige V, Malka D. Treatment of advanced pancreatic cancer. Semin Oncol. 2007;34(2 Suppl 1):S25\u201330.","journal-title":"Semin Oncol"},{"issue":"1","key":"7722_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1073\/pnas.93.1.136","volume":"93","author":"K Chang","year":"1996","unstructured":"Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93(1):136\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"7722_CR9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","volume":"124","author":"R Hassan","year":"2005","unstructured":"Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124(6):838\u201345.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"7722_CR10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/1535-7163.MCT-07-0483","volume":"7","author":"M Li","year":"2008","unstructured":"Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen C, Yao Q. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 2008;7(2):286\u201396.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"7722_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","volume":"16","author":"X He","year":"2017","unstructured":"He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, Rojanasakul Y. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer. 2017;16(1):63.","journal-title":"Mol Cancer"},{"issue":"1","key":"7722_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/bjc.2012.235","volume":"107","author":"T Einama","year":"2012","unstructured":"Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N, Taniguchi M, Kamiyama T, Furukawa H, Matsuno Y, et al. Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer. 2012;107(1):137\u201342.","journal-title":"Br J Cancer"},{"issue":"4","key":"7722_CR13","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3892\/ol.2015.2969","volume":"9","author":"T Einama","year":"2015","unstructured":"Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Ishikawa M, Kawamata F, Konishi Y, Sato M, Tahara M, et al. Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms. Oncol Lett. 2015;9(4):1583\u20139.","journal-title":"Oncol Lett"},{"issue":"8","key":"7722_CR14","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1097\/MPA.0b013e318221bed8","volume":"40","author":"T Einama","year":"2011","unstructured":"Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, Sasaki A, Tahara M, Okada K, Muraoka S, et al. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 2011;40(8):1276\u201382.","journal-title":"Pancreas"},{"issue":"2","key":"7722_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4291\/wjgp.v7.i2.218","volume":"7","author":"T Einama","year":"2016","unstructured":"Einama T, Kawamata F, Kamachi H, Nishihara H, Homma S, Matsuzawa F, Mizukami T, Konishi Y, Tahara M, Kamiyama T, et al. Clinical impacts of mesothelin expression in gastrointestinal carcinomas. World J Gastrointest Pathophysiol. 2016;7(2):218\u201322.","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"1","key":"7722_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00535-013-0773-6","volume":"49","author":"F Kawamata","year":"2014","unstructured":"Kawamata F, Homma S, Kamachi H, Einama T, Kato Y, Tsuda M, Tanaka S, Maeda M, Kajino K, Hino O, et al. C-ERC\/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. J Gastroenterol. 2014;49(1):81\u201392.","journal-title":"J Gastroenterol"},{"issue":"6","key":"7722_CR17","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3892\/ijo.2012.1662","volume":"41","author":"F Kawamata","year":"2012","unstructured":"Kawamata F, Kamachi H, Einama T, Homma S, Tahara M, Miyazaki M, Tanaka S, Kamiyama T, Nishihara H, Taketomi A, et al. Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol. 2012;41(6):2109\u201318.","journal-title":"Int J Oncol"},{"issue":"2","key":"7722_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 2016;6(2):133\u201346.","journal-title":"Cancer Discov"},{"key":"7722_CR19","first-page":"20","volume":"7","author":"R Hassan","year":"2007","unstructured":"Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007;7:20.","journal-title":"Cancer Immun"},{"issue":"2","key":"7722_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s10637-014-0196-0","volume":"33","author":"Y Fujisaka","year":"2015","unstructured":"Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C, et al. Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Investig New Drugs. 2015;33(2):380\u20138.","journal-title":"Investig New Drugs"},{"issue":"73","key":"7722_CR21","doi-asserted-by":"publisher","first-page":"33844","DOI":"10.18632\/oncotarget.26117","volume":"9","author":"T Mizukami","year":"2018","unstructured":"Mizukami T, Kamachi H, Fujii Y, Matsuzawa F, Einama T, Kawamata F, Kobayashi N, Hatanaka Y, Taketomi A. The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model. Oncotarget. 2018;9(73):33844\u201352.","journal-title":"Oncotarget"},{"issue":"4","key":"7722_CR22","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.18632\/oncotarget.23684","volume":"9","author":"N Awasthi","year":"2018","unstructured":"Awasthi N, Monahan S, Stefaniak A, Schwarz MA, Schwarz RE. Inhibition of the MEK\/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Oncotarget. 2018;9(4):5274\u201386.","journal-title":"Oncotarget"},{"issue":"8","key":"7722_CR23","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","volume":"20","author":"TK Bera","year":"2000","unstructured":"Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol. 2000;20(8):2902\u20136.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"7722_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2174\/1871520611313020014","volume":"13","author":"Z Tang","year":"2013","unstructured":"Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anti Cancer Agents Med Chem. 2013;13(2):276\u201380.","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"3","key":"7722_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S0016-5085(03)01064-3","volume":"125","author":"A Scholz","year":"2003","unstructured":"Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, Hauff P, Schirner M, Wiedenmann B, Rosewicz S. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology. 2003;125(3):891\u2013905.","journal-title":"Gastroenterology"},{"issue":"49","key":"7722_CR26","doi-asserted-by":"publisher","first-page":"7781","DOI":"10.1038\/sj.onc.1206966","volume":"22","author":"D DeArmond","year":"2003","unstructured":"DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW. Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene. 2003;22(49):7781\u201395.","journal-title":"Oncogene"},{"issue":"1","key":"7722_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0304-3835(03)00482-8","volume":"201","author":"T Toyonaga","year":"2003","unstructured":"Toyonaga T, Nakano K, Nagano M, Zhao G, Yamaguchi K, Kuroki S, Eguchi T, Chijiiwa K, Tsuneyoshi M, Tanaka M. Blockade of constitutively activated Janus kinase\/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett. 2003;201(1):107\u201316.","journal-title":"Cancer Lett"},{"issue":"6","key":"7722_CR28","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1053\/gast.2002.37075","volume":"123","author":"FR Greten","year":"2002","unstructured":"Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, Schmid RM. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology. 2002;123(6):2052\u201363.","journal-title":"Gastroenterology"},{"issue":"11","key":"7722_CR29","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-08-0095","volume":"6","author":"U Bharadwaj","year":"2008","unstructured":"Bharadwaj U, Li M, Chen C, Yao Q. Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res. 2008;6(11):1755\u201365.","journal-title":"Mol Cancer Res"},{"issue":"2","key":"7722_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1158\/1541-7786.MCR-07-0254","volume":"6","author":"N Uehara","year":"2008","unstructured":"Uehara N, Matsuoka Y, Tsubura A. Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res. 2008;6(2):186\u201393.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"7722_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1042\/BJ20082196","volume":"424","author":"MC Chang","year":"2009","unstructured":"Chang MC, Chen CA, Hsieh CY, Lee CN, Su YN, Hu YH, Cheng WF. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochem J. 2009;424(3):449\u201358.","journal-title":"Biochem J"},{"issue":"12","key":"7722_CR32","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1136\/jcp.2004.025338","volume":"58","author":"X Tan","year":"2005","unstructured":"Tan X, Egami H, Abe M, Nozawa F, Hirota M, Ogawa M. Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. J Clin Pathol. 2005;58(12):1242\u20138.","journal-title":"J Clin Pathol"},{"issue":"1","key":"7722_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1756-9966-31-84","volume":"31","author":"C Zheng","year":"2012","unstructured":"Zheng C, Jia W, Tang Y, Zhao H, Jiang Y, Sun S. Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathway. J Exp Clin Cancer Res. 2012;31(1):84.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6859","key":"7722_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105\u201311.","journal-title":"Nature"},{"issue":"4","key":"7722_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275\u201384.","journal-title":"Nat Rev Cancer"},{"issue":"5935","key":"7722_CR36","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1126\/science.1171837","volume":"324","author":"JM Rosen","year":"2009","unstructured":"Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324(5935):1670\u20133.","journal-title":"Science"},{"issue":"15","key":"7722_CR37","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1007\/s00018-010-0338-2","volume":"67","author":"G Ouyang","year":"2010","unstructured":"Ouyang G, Wang Z, Fang X, Liu J, Yang CJ. Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. Cell Mol Life Sci. 2010;67(15):2605\u201318.","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"7722_CR38","doi-asserted-by":"publisher","first-page":"e13r943","DOI":"10.1371\/journal.pone.0013943","volume":"5","author":"O Awad","year":"2010","unstructured":"Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One. 2010;5(11):e13r943.","journal-title":"PLoS One"},{"issue":"3","key":"7722_CR39","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2009.05.053","volume":"137","author":"MT Mueller","year":"2009","unstructured":"Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009;137(3):1102\u201313.","journal-title":"Gastroenterology"},{"issue":"6","key":"7722_CR40","doi-asserted-by":"publisher","first-page":"e2428","DOI":"10.1371\/journal.pone.0002428","volume":"3","author":"SJ Dylla","year":"2008","unstructured":"Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One. 2008;3(6):e2428.","journal-title":"PLoS One"},{"issue":"1","key":"7722_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/scrt166","volume":"4","author":"B Ortensi","year":"2013","unstructured":"Ortensi B, Setti M, Osti D, Pelicci G. Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res Ther. 2013;4(1):18.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"7722_CR42","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/sj.cdd.4402283","volume":"15","author":"A Eramo","year":"2008","unstructured":"Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15(3):504\u201314.","journal-title":"Cell Death Differ"},{"issue":"1","key":"7722_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ccr.2004.05.032","volume":"6","author":"P Michieli","year":"2004","unstructured":"Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM. Targeting the tumor and its microenvironment by a dual-function decoy met receptor. Cancer Cell. 2004;6(1):61\u201373.","journal-title":"Cancer Cell"},{"issue":"2","key":"7722_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89\u2013103.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7722_CR45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1373\/clinchem.2012.184655","volume":"59","author":"ND Marjanovic","year":"2013","unstructured":"Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in cancer. Clin Chem. 2013;59(1):168\u201379.","journal-title":"Clin Chem"},{"issue":"4","key":"7722_CR46","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bbrc.2017.01.111","volume":"484","author":"V Stankevicius","year":"2017","unstructured":"Stankevicius V, Kunigenas L, Stankunas E, Kuodyte K, Strainiene E, Cicenas J, Samalavicius NE, Suziedelis K. The expression of cancer stem cell markers in human colorectal carcinoma cells in a microenvironment dependent manner. Biochem Biophys Res Commun. 2017;484(4):726\u201333.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"7722_CR47","first-page":"2105","volume":"40","author":"A Shishido","year":"2018","unstructured":"Shishido A, Mori S, Yokoyama Y, Hamada Y, Minami K, Qian Y, Wang J, Hirose H, Wu X, Kawaguchi N, et al. Mesothelial cells facilitate cancer stem-like properties in spheroids of ovarian cancer cells. Oncol Rep. 2018;40(4):2105\u201314.","journal-title":"Oncol Rep"},{"issue":"10","key":"7722_CR48","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1432-0436.2008.00295.x","volume":"76","author":"Y Wang","year":"2008","unstructured":"Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC Jr, Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation. 2008;76(10):1081\u201392.","journal-title":"Differentiation"},{"issue":"3","key":"7722_CR49","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","volume":"68","author":"R Hassan","year":"2010","unstructured":"Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan I. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer. 2010;68(3):455\u20139.","journal-title":"Lung Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07722-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07722-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07722-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T13:06:36Z","timestamp":1614344796000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07722-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7722"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07722-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"2 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Animal Care and Use Committee of National University Corporation Hokkaido University and were conducted under National University Corporation Hokkaido University Regulations on Animal Experimentation. The utilization of the cell lines in this study was also approved by the Ethics Committee of National University Corporation Hokkaido University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}